Evidence map›Paper›PMID 38293237›Full record

ArticlebioRxiv : the preprint server for biology2024

Discovery and Characterization of a Pan-betacoronavirus S2-binding antibody.

Nicole V Johnson, Steven C Wall, Kevin J Kramer, Clinton M Holt, Sivakumar Periasamy, Simone Richardson, Naveenchandra Suryadevara, Emanuele Andreano, Ida Paciello, Giulio Pierleoni and 21 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors.

Nicole V JohnsonDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.
Steven C WallVanderbilt Vaccine Center, Vanderbilt University Medical Center; Nashville, TN 37232, USA.
Kevin J KramerVanderbilt Vaccine Center, Vanderbilt University Medical Center; Nashville, TN 37232, USA.
Clinton M HoltVanderbilt Vaccine Center, Vanderbilt University Medical Center; Nashville, TN 37232, USA.
Sivakumar PeriasamyDepartment of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.
Simone RichardsonNational Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg 2131, South Africa.
Naveenchandra SuryadevaraVanderbilt Vaccine Center, Vanderbilt University Medical Center; Nashville, TN 37232, USA.
Emanuele AndreanoMonoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena 53100, Italy.
Ida PacielloMonoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena 53100, Italy.
Giulio PierleoniMonoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena 53100, Italy.
Giulia PicciniVisMederi Research S.r.l., Siena 53100, Italy.
Ying HuangFlorida Research and Innovation Center, Cleveland Clinic, Port Saint Lucie, FL 34987, USA.
Pan GeFlorida Research and Innovation Center, Cleveland Clinic, Port Saint Lucie, FL 34987, USA.
James D AllenFlorida Research and Innovation Center, Cleveland Clinic, Port Saint Lucie, FL 34987, USA.
Naoko UnoDepartment of Infection Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44196, USA.
Andrea R ShiakolasVanderbilt Vaccine Center, Vanderbilt University Medical Center; Nashville, TN 37232, USA.
Kelsey A PilewskiVanderbilt Vaccine Center, Vanderbilt University Medical Center; Nashville, TN 37232, USA.
Rachel S NargiVanderbilt Vaccine Center, Vanderbilt University Medical Center; Nashville, TN 37232, USA.
Rachel E SuttonVanderbilt Vaccine Center, Vanderbilt University Medical Center; Nashville, TN 37232, USA.
Alexandria A Abu-ShmaisVanderbilt Vaccine Center, Vanderbilt University Medical Center; Nashville, TN 37232, USA.
Robert ParksDuke Human Vaccine Institute, Duke University, Durham, NC 27710, USA.
Barton F HaynesDuke Human Vaccine Institute, Duke University, Durham, NC 27710, USA.
Robert H CarnahanVanderbilt Vaccine Center, Vanderbilt University Medical Center; Nashville, TN 37232, USA.
James E CroweVanderbilt Vaccine Center, Vanderbilt University Medical Center; Nashville, TN 37232, USA.
Emanuele MontomoliVisMederi Research S.r.l., Siena 53100, Italy.
Rino RappuoliMonoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena 53100, Italy.
Alexander BukreyevDepartment of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.
Ted M RossFlorida Research and Innovation Center, Cleveland Clinic, Port Saint Lucie, FL 34987, USA.
Giuseppe A SauttoFlorida Research and Innovation Center, Cleveland Clinic, Port Saint Lucie, FL 34987, USA.
Jason S McLellanDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA.
Ivelin S GeorgievVanderbilt Vaccine Center, Vanderbilt University Medical Center; Nashville, TN 37232, USA.

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · 1995 to 2026
$172.8M
VANDERBILT UNIVERSITY CTSA FOR PEDIATRIC RESEARCHUL1RR024975 · NCRR · VANDERBILT UNIVERSITY · PI BERNARD, GORDON RAPHAEL · 2007 to 2011
$45.7M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MARY Kay WASHINGTON · 2002 to 2026
$29.9M
Shop Module CoreP30EY008126 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI David J. Calkins · 1989 to 2026
$19.6M
B-CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION: Modification for SARS-CoV2 Research75N93019C00074 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CROWE, JAMES E · 2019 to 2024
$10.2M
VANTAGE:Consolidation to create the Vanderbilt Technologies for Advanced GenomicsG20RR030956 · NCRR · VANDERBILT UNIVERSITY · PI PIETENPOL, JENNIFER A · 2010 to 2010
$8.7M
MOLECULAR BIOPHYSICS TRAINING PROGRAM AT VANDERBILTT32GM008320 · NIGMS · VANDERBILT UNIVERSITY · PI CHAZIN, WALTER J. · 1989 to 2023
$7.9M
Human antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2R01AI157155 · NIAID · WASHINGTON UNIVERSITY · PI BARIC, RALPH S, CROWE, JAMES E · 2020 to 2024
$6.0M
Neutralization Fingerprinting Analysis of Polyclonal Antibody Responses against HIV-1R01AI131722 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GEORGIEV, IVELIN · 2017 to 2021
$4.5M
NCI NIH HHS P30 CA068485NCRR NIH HHS G20 RR030956NCRR NIH HHS UL1 RR024975NEI NIH HHS P30 EY008126NIAID NIH HHS 75N93019C00074NIAID NIH HHS R01 AI131722NIAID NIH HHS R01 AI157155NIDDK NIH HHS P30 DK058404NIGMS NIH HHS T32 GM008320
6 · The paper itself

Abstract

Three coronaviruses have spilled over from animal reservoirs into the human population and caused deadly epidemics or pandemics. The continued emergence of coronaviruses highlights the need for pan-coronavirus interventions for effective pandemic preparedness. Here, using LIBRA-seq, we report a panel of 50 coronavirus antibodies isolated from human B cells. Of these antibodies, 54043-5 was shown to bind the S2 subunit of spike proteins from alpha-, beta-, and deltacoronaviruses. A cryo-EM structure of 54043-5 bound to the pre-fusion S2 subunit of the SARS-CoV-2 spike defined an epitope at the apex of S2 that is highly conserved among betacoronaviruses. Although non-neutralizing, 54043-5 induced Fc-dependent antiviral responses, including ADCC and ADCP. In murine SARS-CoV-2 challenge studies, protection against disease was observed after introduction of Leu234Ala, Leu235Ala, and Pro329Gly (LALA-PG) substitutions in the Fc region of 54043-5. Together, these data provide new insights into the protective mechanisms of non-neutralizing antibodies and define a broadly conserved epitope within the S2 subunit.

Identifiers

PMID38293237
PMCPMC10827111

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.